Liquid Array Protein Assay Platform

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,999.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI077249-01A1
Agency Tracking Number:
AI077249
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ARRAYOMICS, INC.
ARRAYOMICS, INC., 9909 HIBERT ST, STE A, SAN DIEGO, CA, 92131
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
140695847
Principal Investigator:
DAVID ROTHWARF
(858) 245-2435
DROTHWARF@ARRAYOMICS.COM
Business Contact:
() -
drothwarf@arrayomics.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The aim of this project is to extend application of a novel liquid array' platform, based on Encoded Sortable Particle (ESP) technology, into the protein assay realm. ESPs are optically-encoded microfabricated particle s that can be manipulated using magnetic force. We will adapt our ESP-based liquid array system, which has already been successfully applied in the DNA space, to incorporate antibody-based protein detection assays in Phase I, and we will extend the scope o f protein assay coverage in Phase II. Phase I will consist of a 6-plex cytokine detection analysis, while Phase II is intended to accommodate assays of 1000-plex or more. In the protein space the ESP platform has significant advantages in cost, throughput, scalability, ease of use, and flexibility over existing bead-based liquid array and fixed array platforms. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease state s, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV). PUBLIC HEALTH RELEVANCE: ESP technology as applied to the protein assay space will provid e a broad platform for many different kinds of assays. The ESP platform is intrinsically versatile, and has the potential to be used in basic biomedical research, as well as high-throughput discovery and clinical diagnostics. The ability to control the par ticles magnetically (in a manner significantly different from magnetic beads) is a significant advantage. This technology should be useful in the diagnosis and prognosis of a variety of disease states, including cancer, heart disease, arthritis and inflamm atory diseases, kidney disease, and infectious diseases (e.g. HIV).

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government